Methods and compositions for stabilizing trans-splicing intein modified proteases
Methods for producing a trans-splicing intein-modified protease with enhanced solubility and regulating its activity are described. Intein-modified proteases having enhanced solubility and polynucleotides encoding the same are provided. Methods of storing trans-splicing proteases are also described.
1. An intein-modified protease comprising: a first precursor and a second precursor: the first precursor comprises an N-extein of a target protease fused to a solubility enhanced N-intein of a trans-splicing intein, and the carboxy terminus of the N-extein is fused to the amino terminus of the solubility enhanced N-intein, the solubility enhanced N-intein comprises an N-intein and a first solubility enhancer, and the carboxy terminus of the N-intein is fused to the first solubility enhancer by a first linker; the second precursor comprises a solubility enhanced C-intein of the trans-splicing intein fused to a C-extein of the target protease, and the carboxy terminus of the solubility enhanced C-intein is fused to the amino terminus of the C-extein, the solubility enhanced C-intein comprises a C-intein and a second solubility enhancer, and the second solubility enhancer is fused to the amino terminus of the C-intein by a second linker; each of the first solubility enhancer and the second solubility enhancer comprises the thioredoxin domain Trx, and the first precursor is separated from the second precursor prior to trans-splicing; wherein the intein-modified protease has enhanced solubility and reduced activity compared to the target protease and the activity of the target protease is at least partially restored upon trans-splicing of the intein-modified protease and fusion of the N-extein and the C-extein, and wherein the first precursor consists of an amino acid sequence with at least 90% identity to SEQ ID NO: 1, and the second precursor consists of an amino acid sequence with at least 90% identity to SEQ ID NO: 2.
2. The intein-modified protease of claim 1 , wherein the first precursor comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 1, and the second precursor comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 2.
3. A composition comprising: a first precursor of an intein-modified protease and a second precursor of an intein-modified protease, the first precursor comprises an N-extein of a target protease fused to a solubility enhanced N-intein of a trans-splicing intein, and the carboxy terminus of the N-extein is fused to the amino terminus of the solubility enhanced N-intein, the solubility enhanced N-intein comprises an N-intein and a first solubility enhancer, and the carboxy terminus of the N-intein is fused to the first solubility enhancer by a first linker; the second precursor comprises a solubility enhanced C-intein of the trans-splicing intein fused to a C-extein of the target protease, and the carboxy terminus of the solubility enhanced C-intein is fused to the amino terminus of the C-extein, the solubility enhanced C-intein comprises a C-intein and a second solubility enhancer, and the second solubility enhancer is fused to the amino terminus of the C-intein by a second linker; each of the first solubility enhancer and the second solubility enhancer comprises the thioredoxin domain Trx, and the first precursor is separated from the second precursor prior to trans-splicing; wherein the intein-modified protease has enhanced solubility and reduced activity compared to the target protease and the activity of the target protease is at least partially restored upon trans-splicing of the intein-modified protease and fusion of the N-extein and the C-extein, and wherein the first precursor consists of an amino acid sequence with at least 90% identity to SEQ ID NO: 1, and the second precursor consists of an amino acid sequence with at least 90% identity to SEQ ID NO: 2.
4. A home care product comprising an intein-modified protease of claim 1 , or the composition of claim 3 .
5. The home care product of claim 4 further comprising one or more effectors, wherein the one or more effectors is capable of suppressing trans-splicing.
6. The home care product of claim 5 , wherein the suppressing is reversible.
7. The home care product of claim 5 , wherein the home care product further comprises at least one agent selected from the group consisting of: detergent, soap, industrial cleaner, and dish washing liquid.
8. The home care product of claim 5 , wherein the one or more effectors are selected from the group consisting of: sodium salt supplements, potassium salt supplements, sodium chloride, tetrasodium iminodisuccinate, disodium succinate, disodium tartrate, potassium lactate, potassium citrate, potassium chloride, sodium nicotinate, sodium polyaspartate, and sodium polyacrylate.
9. The intein-modified protease of claim 1 , wherein the target protease is a Savinase.
10. The composition of claim 3 , wherein the target protease is a Savinase.